Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventri
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:7/30/2014)... July 30, 2014 PuraMed BioScience ® ... of over-the-counter (OTC) medicinal and healthcare products, announced ... M name along with the name,s red and ... the trademarked name MigraPure ®  going forward. ... PuraMed,s homeopathic, natural migraine pain reliever will be ...
(Date:7/30/2014)... 30, 2014  Today the US Surgeon General issued the ... tanning or sun burns stating they can lead directly to ... Boris Lushniak , says that "skin cancer is a major ... much exposure to indoor and outdoor ultraviolet light is a ... Medicine, in Boca Raton, Florida , ...
(Date:7/30/2014)... July 30, 2014  El Camino Hospital, a leader ... is utilizing the Leaf Patient Monitoring system to help ... movement of patients susceptible to bed sores. ... 138-patient study of the system, which showed dramatic improvement ... patients regularly is the one of the most effect ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Indoor and Outdoor Sun Tanning or Sun Burns Directly Linked to Deadly Melanoma Skin Cancer 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3
... Conn., March 30, 2011 Attendees of the 60th ... New Orleans, La., can see first hand the benefits ... Available for sale in the U.S., Synapse 3D is ... directly into Synapse® Cardiovascular, Fujifilm,s CVIS / C-PACS. During ...
... PORT WASHINGTON, N.Y., March 30, 2011 Premier Heart, LLC ... 11, the 60th Annual Scientific Sessions and Expo of the ... in New Orleans. The MCG offers completely non-invasive cardiac testing ... diagnosis" according to its latest US FDA 510K Clearance.  MCG ...
Cached Medicine Technology:Fujifilm Highlights Synapse® 3D at ACC 2Fujifilm Highlights Synapse® 3D at ACC 3Premier Heart to Exhibit its Multifunction CardioGram (MCG™) at American College of Cardiology in New Orleans April 2-5 2
(Date:7/30/2014)... can happen in an instant: A small child pulls up ... critically injured when the furniture tips over. "Every parent ... homes and imagine what could tip over, fall off walls ... becoming a reality," Dr. Alex Rosenau, president of the American ... Between 2009 and 2011, roughly 43,000 people ended up ...
(Date:7/30/2014)... New York (PRWEB) July 30, 2014 ... uncontrollable brain bleeding has filed a Xarelto lawsuit ( ... the blood thinner, Bernstein Liebhard LLP reports. According to ... for the District of Vermont on July 25th, the ... when he suffered an irreversible brain bleed that ultimately ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- Some obese people ... the reward centers in their brains when they see ... how this mutation triggers feelings of pleasure and gratification ... help improve strategies designed to prevent overeating, the scientists ... obese. Obesity is typically caused by a combination ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long after their acute illness ... led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or even years after an ...
(Date:7/30/2014)... 2014 LTC Consumer, an independent, free online ... insurance, features an Instant Quote tool on its website, ... LTC Consumer. Quotes are free and unlimited. , The ... seven areas – including age, gender, and state of residence ... (you don’t need to enter any contact information to get ...
Breaking Medicine News(10 mins):Health News:Tip-Over Furniture Can Kill Kids 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Gene Mutation May Make Food More Tempting 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2
... By Kathleen Doheny HealthDay Reporter , TUESDAY, ... two strains of human papillomavirus (HPV) that are most likely ... with the Pap test, may be more accurate for many ... And, for those women who are HPV-positive, using the ...
... surrounding the Food and Drug Administration,s ruling that Avastin ... cancer, a new multinational Phase III clinical trial shows ... cancer patients when given before surgery. At ... Oncology, the nation,s premier association of clinical oncologists, Harry ...
... treated at a U.S. military hospital in Afghanistan often ... the September issue of Infection Control and Hospital ... Epidemiology of America. The findings underscore the need for ... soldiers and local patients are treated, the study,s authors ...
... Toronto,s psychology department show that people who use ... surgery are viewed more negatively than those who use ... younger adults are more negative about using anti-aging methods ... the rapid growth of the anti-aging cosmetic industry, age ...
... HealthDay Reporter , TUESDAY, Aug. 23 ... (ADHD) have a much higher risk of developing a ... ADHD experts, the current observation does not come as ... children with ADHD stand a much higher chance of ...
... responsible for cells of different tissues of our body to ... matching receptors on the surface of their target cells and ... single genetic alteration can be sufficient for the whole system ... for such a growth factor or for the matching receptor ...
Cached Medicine News:Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3Health News:Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients 2Health News:Study: Afghan patients a common source of drug-resistant bacteria 2Health News:U of T research shows anti-aging techniques not yet viewed as acceptable 2Health News:Study Links Writing Difficulties to ADHD 2Health News:Study Links Writing Difficulties to ADHD 3Health News:Stop signal for leukemia stem cells 2
... Acclaim 7000 Nd:YAG laser allows you ... cosmetic procedures such as hair removal, ... our Dermique LaserFACIAL for sun-damaged skin. ... parameters for customizing treatment based on ...
... full system for hair removal, with scanner and ... hair reduction system. The 90W laser generates ... hair bulb and bugle. To ease and optimise ... tissue through the MedArt® 413 scanner.,The laser beam ...
Reusable Components Compatible with VERSASTEP™ Reposable Access System....
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
Medicine Products: